• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

升级利用蒽环类药物:新的作用机制、毒理学和药理学。

Upcycling the anthracyclines: New mechanisms of action, toxicology, and pharmacology.

机构信息

Department of Pharmaceutical Sciences, College of Pharmacy, Ferris State University, Big Rapids, MI, USA.

Department of Pharmaceutical Sciences, School of Pharmacy and Health Professions, University of Maryland Eastern Shore, Princess Anne, MD, USA.

出版信息

Toxicol Appl Pharmacol. 2023 Jan 15;459:116362. doi: 10.1016/j.taap.2022.116362. Epub 2022 Dec 30.

DOI:10.1016/j.taap.2022.116362
PMID:36592899
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9840691/
Abstract

The anthracyclines are a family of natural products isolated from soil bacteria with over 2000 chemical representatives. Since their discovery seventy years ago by Waksman and co-workers, anthracyclines have become one of the best-characterized anticancer chemotherapies in clinical use. The anthracyclines exhibit broad-spectrum antineoplastic activity for the treatment of a variety of solid and liquid tumors, however, their clinical use is limited by their dose-limiting cardiotoxicity. In this review article, we discuss the toxicity of the anthracyclines on several organ systems, including new insights into doxorubicin-induced cardiotoxicity. In addition, we discuss new medicinal chemistry developments in the biosynthesis of new anthracycline analogs and the synthesis of new anthracycline analogs with diminished cardiotoxicity. Lastly, we review new studies that describe the repurposing of the anthracyclines, or "upcycling" of the anthracyclines, as anti-infective agents, or drugs for niche indications. Altogether, the anthracyclines remain a mainstay in the clinic with a potential new "lease on life" due to deeper insight into the mechanism underlying their cardiotoxicity and new developments into potential new clinical indications for their use. Keywords: Anthracycline, chemotherapy, toxicology, medicinal chemistry, biosynthesis.

摘要

蒽环类抗生素是一类从土壤细菌中分离出来的天然产物,拥有超过 2000 种化学代表物。自 70 年前 Waksman 及其同事发现以来,蒽环类抗生素已成为临床应用中最具特征性的抗癌化疗药物之一。蒽环类抗生素对多种实体瘤和液体瘤具有广谱抗肿瘤活性,但其临床应用受到其剂量限制的心脏毒性的限制。在这篇综述文章中,我们讨论了蒽环类抗生素对几个器官系统的毒性,包括对多柔比星诱导的心脏毒性的新见解。此外,我们还讨论了新的药物化学发展,包括新蒽环类抗生素类似物的生物合成和心脏毒性降低的新蒽环类抗生素类似物的合成。最后,我们回顾了描述蒽环类抗生素重新定位或“升级利用”为抗感染药物或利基适应症药物的新研究。总之,由于对其心脏毒性的机制有了更深入的了解,以及对其潜在新临床应用的新发展,蒽环类抗生素仍然是临床治疗的主要药物,具有新的“生命力”。关键词:蒽环类抗生素、化疗、毒理学、药物化学、生物合成。

相似文献

1
Upcycling the anthracyclines: New mechanisms of action, toxicology, and pharmacology.升级利用蒽环类药物:新的作用机制、毒理学和药理学。
Toxicol Appl Pharmacol. 2023 Jan 15;459:116362. doi: 10.1016/j.taap.2022.116362. Epub 2022 Dec 30.
2
In vitro modeling of the structure-activity determinants of anthracycline cardiotoxicity.蒽环类药物心脏毒性结构 - 活性决定因素的体外建模
Cell Biol Toxicol. 2007 Jan;23(1):49-62. doi: 10.1007/s10565-006-0143-8. Epub 2006 Oct 9.
3
What is considered cardiotoxicity of anthracyclines in animal studies.在动物研究中,什么被认为是蒽环类药物的心脏毒性。
Oncol Rep. 2020 Sep;44(3):798-818. doi: 10.3892/or.2020.7688. Epub 2020 Jul 14.
4
[Cardiooncology: Current Aspects of Prevention of Anthracycline Toxicity].[心脏肿瘤学:蒽环类药物毒性预防的当前研究进展]
Kardiologiia. 2016 Dec;56(12):72-79.
5
Inhibition of membrane-associated calcium-independent phospholipase A2 as a potential culprit of anthracycline cardiotoxicity.抑制膜相关的钙非依赖性磷脂酶A2作为蒽环类药物心脏毒性的潜在元凶。
Cancer Res. 2003 Sep 15;63(18):5992-8.
6
Anthracycline degradation in cardiomyocytes: a journey to oxidative survival.心肌细胞中蒽环类药物的降解:走向氧化存活的旅程。
Chem Res Toxicol. 2010 Jan;23(1):6-10. doi: 10.1021/tx9003424.
7
[Early detection of anthracyclines cardiotoxicity by tissue Doppler echocardiography about 45 cases at Abidjan institute of cardiology].[阿比让心脏病学研究所利用组织多普勒超声心动图对约45例患者进行蒽环类药物心脏毒性的早期检测]
Ann Cardiol Angeiol (Paris). 2013 Feb;62(1):28-33. doi: 10.1016/j.ancard.2012.03.002. Epub 2012 Mar 23.
8
Preclinical assessment of anthracycline cardiotoxicity in laboratory animals: predictiveness and pitfalls.实验室动物中蒽环类药物心脏毒性的临床前评估:预测性与陷阱
Cell Biol Toxicol. 2007 Jan;23(1):27-37. doi: 10.1007/s10565-006-0142-9. Epub 2006 Oct 13.
9
4'-Epidoxorubicin to re-explore anthracycline degradation in cardiomyocytes.4'-表阿霉素用于重新探究心肌细胞中的蒽环类药物降解情况。
Chem Res Toxicol. 2009 Jun;22(6):978-83. doi: 10.1021/tx900039p.
10
New iron chelators in anthracycline-induced cardiotoxicity.蒽环类药物所致心脏毒性中的新型铁螯合剂
Cardiovasc Toxicol. 2007;7(2):145-50. doi: 10.1007/s12012-007-0020-6.

引用本文的文献

1
Metabolomic profiling and biomarker identification for early detection and therapeutic targeting of doxorubicin-induced cardiotoxicity.用于阿霉素诱导的心脏毒性早期检测和治疗靶点的代谢组学分析及生物标志物鉴定
Front Cell Dev Biol. 2025 Apr 10;13:1543636. doi: 10.3389/fcell.2025.1543636. eCollection 2025.
2
Design of New Daunorubicin Derivatives with High Cytotoxic Potential.具有高细胞毒性潜力的新型柔红霉素衍生物的设计
Int J Mol Sci. 2025 Jan 31;26(3):1270. doi: 10.3390/ijms26031270.
3
The Daunomycin: Biosynthesis, Actions, and the Search for New Solutions to Enhance Production.柔红霉素:生物合成、作用及提高产量的新解决方案探索
Microorganisms. 2024 Dec 19;12(12):2639. doi: 10.3390/microorganisms12122639.
4
Harnessing bacterial metabolites for enhanced cancer chemotherapy: unveiling unique therapeutic potentials.利用细菌代谢物增强癌症化疗:揭示独特的治疗潜力。
Arch Microbiol. 2024 Oct 29;206(11):449. doi: 10.1007/s00203-024-04179-x.
5
Management of a Patient with Cardiovascular Disease Should Include Assessment of Primary and Secondary Immunodeficiencies: Part 2-Secondary Immunodeficiencies.心血管疾病患者的管理应包括对原发性和继发性免疫缺陷的评估:第2部分——继发性免疫缺陷。
Healthcare (Basel). 2024 Oct 4;12(19):1977. doi: 10.3390/healthcare12191977.
6
Diverse Combinatorial Biosynthesis Strategies for C-H Functionalization of Anthracyclinones.多样的组合生物合成策略用于蒽环类抗生素 C-H 功能化。
ACS Synth Biol. 2024 May 17;13(5):1523-1536. doi: 10.1021/acssynbio.4c00043. Epub 2024 Apr 25.
7
Determination of and Effects of Taxifolin and Epirubicin on Epithelial-Mesenchymal Transition in Mouse Breast Cancer Cells.二氢槲皮素和表阿霉素对小鼠乳腺癌细胞上皮-间质转化的影响及其机制研究。
Technol Cancer Res Treat. 2024 Jan-Dec;23:15330338241241245. doi: 10.1177/15330338241241245.
8
Recent advances in the cardiotoxicity of anti-cancer drugs: Navigating the landscape of anthracycline-induced cardiotoxicity.抗癌药物心脏毒性的最新进展:解读蒽环类药物诱导的心脏毒性情况
Toxicol Appl Pharmacol. 2024 Jan;482:116791. doi: 10.1016/j.taap.2023.116791. Epub 2023 Dec 14.
9
Metabolomics and Network Analyses Reveal Phenylalanine and Tyrosine as Signatures of Anthracycline-Induced Hepatotoxicity.代谢组学和网络分析揭示苯丙氨酸和酪氨酸是蒽环类药物诱导肝毒性的特征标志物。
Pharmaceuticals (Basel). 2023 May 26;16(6):797. doi: 10.3390/ph16060797.
10
Curcumin protects against doxorubicin induced oxidative stress by regulating the Keap1-Nrf2-ARE and autophagy signaling pathways.姜黄素通过调节 Keap1-Nrf2-ARE 和自噬信号通路来防止阿霉素引起的氧化应激。
Psychopharmacology (Berl). 2023 May;240(5):1179-1190. doi: 10.1007/s00213-023-06357-z. Epub 2023 Mar 22.

本文引用的文献

1
Relevance of Ferroptosis to Cardiotoxicity Caused by Anthracyclines: Mechanisms to Target Treatments.铁死亡与蒽环类药物引起的心脏毒性的相关性:靶向治疗机制
Front Cardiovasc Med. 2022 Jun 13;9:896792. doi: 10.3389/fcvm.2022.896792. eCollection 2022.
2
Recycled Translation: Repurposing Drugs for Stroke.再利用药物治疗中风。
Transl Stroke Res. 2022 Dec;13(6):866-880. doi: 10.1007/s12975-022-01000-z. Epub 2022 Feb 26.
3
Anthracyclines: biosynthesis, engineering and clinical applications.蒽环类抗生素:生物合成、工程改造及临床应用
Nat Prod Rep. 2022 Apr 20;39(4):814-841. doi: 10.1039/d1np00059d.
4
Synthetic (,-Dimethyl)doxorubicin Glycosyl Diastereomers to Dissect Modes of Action of Anthracycline Anticancer Drugs.合成(−二甲基)多柔比星糖苷非对映异构体解析蒽环类抗癌药物的作用模式。
J Org Chem. 2021 Apr 16;86(8):5757-5770. doi: 10.1021/acs.joc.1c00220. Epub 2021 Mar 30.
5
Cardiotoxic Effect of Modern Anthracycline Dosing on Left Ventricular Ejection Fraction: A Systematic Review and Meta-Analysis of Placebo Arms From Randomized Controlled Trials.现代蒽环类药物剂量对左心室射血分数的心脏毒性作用:来自随机对照试验安慰剂臂的系统评价和荟萃分析。
J Am Heart Assoc. 2021 Mar 16;10(6):e018802. doi: 10.1161/JAHA.120.018802. Epub 2021 Mar 4.
6
Repurposing medications.药物再利用。
Ocul Surf. 2021 Jan;19:336-340. doi: 10.1016/j.jtos.2020.11.012. Epub 2020 Nov 26.
7
Doxorubicin and Aclarubicin: Shuffling Anthracycline Glycans for Improved Anticancer Agents.多柔比星和阿克拉霉素: shuffling 蒽环糖苷以改善抗癌药物。
J Med Chem. 2020 Nov 12;63(21):12814-12829. doi: 10.1021/acs.jmedchem.0c01191. Epub 2020 Oct 16.
8
Structure-based drug repurposing to inhibit the DNA gyrase of Mycobacterium tuberculosis.基于结构的药物重定位以抑制结核分枝杆菌的 DNA 回旋酶。
Biochem J. 2020 Nov 13;477(21):4167-4190. doi: 10.1042/BCJ20200462.
9
New insights into the activities and toxicities of the old anticancer drug doxorubicin.对老抗癌药物阿霉素的活性和毒性的新认识。
FEBS J. 2021 Nov;288(21):6095-6111. doi: 10.1111/febs.15583. Epub 2020 Oct 19.
10
Uncoupling DNA damage from chromatin damage to detoxify doxorubicin.将 DNA 损伤与染色质损伤分离以解毒阿霉素。
Proc Natl Acad Sci U S A. 2020 Jun 30;117(26):15182-15192. doi: 10.1073/pnas.1922072117. Epub 2020 Jun 17.